Charlottesville, Virginia 22908


Gadolinium contrast agents are frequently administered for MRI imaging. Very little is known of its toxicity outside of patients with reduced renal function.

Study summary:

Gadolinium contrast is administered to patients during MRI imaging. Recently, the investigators have observed potential gadolinium toxicity in some patients. To investigate this, the investigators propose to collect clinical data and lab data obtained as a part of clinical care. The investigators also plan to obtain 25 cc of peripheral blood at 2-4 weeks, 4-6 weeks and again at 3 months to identify unique monocyte signatures, gene polymorphisms, and to quantitate circulating fibrocytes (in fresh blood and after culture). Plan to enroll 15 patients with kidney, pancreas or liver transplant and exposed to gadolinium contrast agents, 15 non-transplant patients exposed to gadolinium contrast and 30 age- and sex-matched healthy controls not exposed to gadolinium contrast.


Inclusion Criteria: - Renal, pancreas or liver transplant OR those without organ transplant OR controls - Age 18-70 - Both gender - Exposure to gadolinium contrast agents (no exposure in controls) - Have had a transplant, have had a contrast dye with an MRI - Have not had a transplant and have had a contrast dye with an MRI - Healthy person who has not had an MRI or gadolinium for any other reason. Exclusion Criteria: - End stage kidney disease or Stage 5 - Previous diagnosis of Nephrogenic Systemic Fibrosis



Primary Contact:

Principal Investigator
Sundararaman Swaminathan, MD
University of Virginia

Sundararaman Swaminathan, MD
Phone: 434-982-3577

Backup Contact:


Location Contact:

Charlottesville, Virginia 22908
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.